The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

European Union looks to sue AstraZeneca over delivery shortfall

Thu, 22nd Apr 2021 11:54

(Alliance News) - The European Commission is looking to launch legal action against AstraZeneca PLC for underdelivering Covid-19 vaccine doses to the European Union, hobbling the bloc's early rollout of jabs, EU diplomats said on Thursday.

The EU executive informed member state envoys of its plans on Wednesday, the diplomats told AFP, confirming information first published by the Politico website.

They said any lawsuit against AstraZeneca would begin in a Belgian court, the jurisdiction agreed under the commission's contract with the British-Swedish pharmaceutical company.

One EU diplomat said the commission wanted EU member states – which also had a role in negotiating the vaccine contracts for the bloc – to back the lawsuit and to say so by the end of this week.

"The problem is that the member states do not know the complaint" being formulated, the diplomat said. "It is a sensitive procedure and you do not want to further damage trust in the vaccine."

Anther diplomat said that "not all member states are in agreement" on taking the company to court, stressing that their aim was simply to have AstraZeneca deliver the doses it had promised in its contract.

So far, AstraZeneca has delivered just 30 million of the 120 million doses it had promised, and it has warned it will likewise provide just 70 million of the 180 million more meant to be delivered over the rest of this year.

Public confidence in the AstraZeneca jab has taken a blow after the European Medicines Regulator said it was likely linked to a very rare, but often fatal, form of blood clots affecting the brain. 

The EMA and the commission have not changed their stance on a general use of AstraZeneca, saying its benefits outweighed the risks, but several EU countries have restricted it to older citizens, aged over 50, 55 or 60.

- "Best efforts" -

AstraZeneca's French-Australian boss, Pascal Soriot, has argued that his company's contract with the EU binds it only to a "best reasonable efforts" clause. 

But the commission says the rest of the contract shows greater legal responsibility than that, and EU diplomats and lawmakers have pointed out that the company has largely delivered promised doses to Britain, where it is headquartered.

The European Commission did not confirm the reports of planned legal action.

"What matters is that we ensure the delivery of a sufficient number of doses in line with the company's earlier commitments," a spokesman said.

"Together with the member states, we are looking at all options to make this happen," he said.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.